223 results about "Ingestion" patented technology

The invention relates to the technical field of medical apparatus and instruments, and discloses a long-acting gastric retention drug delivery device which can enter the stomach in an oral self-ingestion mode, further realizes size change through expansion of an elastic assembly, enhances the mechanical strength of the elastic assembly through a water-induced hard polymer, and avoids extrusion deformation and emptying through the pylorus of the stomach. The device comprises a medicine carrying assembly, an elastic assembly and a connecting assembly, the medicine carrying assembly comprises a plurality of medicine carrying pieces, and each medicine carrying piece is provided with a medicine carrying cavity. The elastic assembly comprises a plurality of elastic pieces, and the first ends of the elastic pieces are connected with one another, so that the elastic assembly is in a star shape in the unfolded state. The outer layer of the elastic assembly is coated with a reinforcing film, and the reinforcing film is formed by curing a water-hardened polymer and can be gradually converted into rigidity from flexibility in a water-based environment. The connecting assembly comprises a plurality of connecting pieces, the second end of one elastic piece is connected with one medicine carrying piece through one connecting piece, and the connecting pieces are decomposed under preset conditions, so that the medicine carrying pieces and the elastic assembly are separated and discharged out of the body in a non-invasive mode.

The invention discloses a composite microbial preparation for treating obesity of pet dogs and application of the composite microbial preparation, and belongs to the technical field of microbial preparations. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146, and the preservation number of the lactobacillus reuteri GBW1146 is CGMCC (China General Microbiological Culture Collection Center) No. 34455. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146. The compound microbial preparation can remarkably reduce digestion and absorption of intestinal tracts of dogs on fat and reduce triglyceride and cholesterol levels in blood, so that the average food intake and average calorie consumption of the dogs are reduced, and finally the effect of reducing obesity of the pets is achieved. The compound microbial preparation provided by the invention enhances the competitiveness of the pet feed additive and series products thereof in China in the international market, and has a wide application prospect.

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

Doubly labeled water with enhanced protocol. One embodiment is a method including providing, to a user, a doubly labeled water (DLW) dose for the user to ingest, the DLW dose including deuterium and oxygen-18, wherein an amount of the deuterium is less than 0.12 grams per kilogram (g / kg) of body water of the user, and wherein an amount of the oxygen-18 is less than 0.18 g / kg of body water of the user. The method also includes receiving, from the user, a non-cooled shipment of urine samples collected in connection with ingestion of the DLW dose, wherein the urine samples remain uncooled after collection and during transit for a period of up to 24 days. The method further includes processing the urine samples with a liquid water isotope analyzer to determine one or more metabolic parameters of the user.

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The invention discloses application of 2-hydroxybutyric acid and derivatives thereof in preparation of drugs for preventing and / or treating metabolic diseases, and belongs to the technical field of biological medicines. Experiments prove that the 2-hydroxybutyric acid and the derivatives thereof can effectively inhibit obesity induced by high fat diet and reduce body fat, and have good improvement effects on related glucose and lipid metabolism disorders, including reduction of fasting blood-glucose, improvement of glucose tolerance, reduction of liver lipid deposition and improvement of liver functions. More importantly, the 2-hydroxybutyric acid does not affect ingestion, the metabolism improvement effect of the 2-hydroxybutyric acid depends on activation of fat heat production, and energy consumption can be directly promoted, so that obvious gastrointestinal tract adverse reactions cannot be generated, and potential mental side effects of existing appetite inhibiting drugs do not exist.

The invention provides a traditional Chinese medicine composition for relieving chemotherapy side effects, traditional Chinese medicine compound essential oil and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 1-9 parts of pericarpium citri reticulatae, 1-9 parts of pericarpium citri reticulatae viride, 1-9 parts of clove, 1-9 parts of fennel, 1-9 parts of ginger, 1-9 parts of pogostemon cablin and 1-9 parts of rhizoma atractylodis. The traditional Chinese medicine composition is mainly used for treating abdominal distension pain, nausea and vomiting caused by damp turbidity resistance and spleen and stomach disharmony through the effects of promoting qi circulation, removing dampness, strengthening the spleen and harmonizing the stomach. Experimental results show that the traditional Chinese medicine compound essential oil prepared from the traditional Chinese medicine composition can reduce allotriophagia behaviors of rats and improve ingestion and drinking habits, has a recovery effect on metabolite disorder caused by chemotherapy-related nausea and vomiting, and provides a theoretical basis for a supplementary treatment method of chemotherapy-related nausea and vomiting.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

Beta-hydroxybutyrate compositions formulated for ingestion by oral delivery as a beverage include a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate, wherein the beta-hydroxybutyrate can be enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate, wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

The invention discloses a Dunella strain, polysaccharide produced by the Dunella strain and application of the Dunella strain. The preservation number of the Duronella G3 is CCTCC (China Center For Type Culture Collection) NO: M 2024137, and the exopolysaccharide TDG3 produced by the Duronella G3 is used as a TLR4 / DC-SIGN dual receptor agonist and has the effect of remarkably reducing body weight. The exopolysaccharide TDG3 disclosed by the invention can obviously reduce the appetite of mice, reduce the food intake, reduce the body weight and reduce the content of adipose tissues, can also relieve or prevent liver fatty degeneration caused by obesity, is safe and non-toxic, is suitable for preparing the medicines for reducing fat and losing weight, and has a relatively good clinical application value and a wide application prospect.

A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolism parameters in motor and sedentary mammals by oral intake of low doses of D-ribose, thereby promoting overall metabolic health in mammals.

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and / or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and / or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

The invention includes an orally ingestible delivery system for releasing a therapeutic agent within an intestine of a mammal, where the system includes the therapeutic agent and a differentially permeable capsule system containing the therapeutic agent within a therapeutic agent compartment, with the differentially permeable capsule system dimensionally adapted for oral ingestion and for passage into a stomach of the mammal and thence into the intestine, wherein the differentially permeable capsule system comprises an acid-resistant shell and a dispersible acid barrier, wherein the dispersible acid barrier forms while the orally-ingestible delivery system is in the stomach; and wherein the dispersible acid barrier is dispersed in the intestine, thereby permitting enzymes in the intestine to reach the therapeutic agent compartment. The invention also includes methods of manufacturing the system and methods for its use.

An expandable member (201, 301) for an ingestible device (200, 300) includes a first section (202, 302) and a second section (204, 304). The first section includes a plurality of pockets (202a, 202b, 202c, 302a, 302b, 302c) partially separated from each other and fluidly coupled together by a foldable joint (202ab, 202bc, 302ab, 302bc) positioned therebetween. The plurality of pockets is configured to contain a first substance (212, 312). The second section includes a reservoir (204a, 304a) configured to contain a second substance (214, 314). The first section is configured to be folded via the foldable joint after being filled with the first substance such that the pockets are arranged in a rolled or an overlapping configuration. The expandable member is structured to expand to occupy a space in a GI tract of a subject upon ingestion of the ingestible device.

The utility model discloses an arma chinensis fallou feeding device, which relates to the field of insect feeding equipment, and comprises a feeding box, a liquid storage container and a liquid suction feeding part, the top of the feeding box is provided with a liquid inlet, the bottom of the liquid storage container is connected with a liquid guide pipe, the liquid guide pipe is communicated with the liquid inlet, and the liquid guide pipe is provided with a flow regulator; the liquid suction feeding part is vertically arranged in the feeding box, and the bottom of the liquid suction feeding part is in contact with feeding liquid in the feeding box and adsorbs the feeding liquid; by arranging the liquid storage container and the liquid guide pipe, feeding liquid can be continuously supplied to the feeding box, the liquid suction feeding part is arranged to adsorb the feeding liquid for arma chinensis to suck, and the feeding speed of the feeding liquid is adjusted through the flow adjuster, so that the feeding speed of the arma chinensis and the feeding speed of the feeding liquid are balanced; the method that in the prior art, soaked sponge, cotton and the like are placed above a rearing cage gauze for feeding is replaced, the feeding difficulty is greatly reduced, the feeding operation time of a breeder is saved, and the bug breeding technology is standardized.

A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

Disclosed herein include methods and compositions suitable for use in modulation of aversive taste tolerance. In some embodiments, ingestion of sodium and / or aversive substances is reduced. Also disclosed include methods for identifying modulators for aversive taste tolerance.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and / or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and / or rapid dissolution / degradation in a physiological environment (e.g., intestinal environment) and / or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution / degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and / or enhancement agents with a structural material necessary for gastric residence but configured for controlled and / or tunable degradation / dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

The utility model discloses a non-toppling type confrontable abundant feeding device for herbivorous animals, which comprises a non-toppling type base with a hemispherical structure, a stand column shaft is vertically arranged at the center of the surface of the non-toppling type base, and the stand column shaft is detachably connected with the non-toppling type base; the stand column shaft is sleeved with a feeding barrel, and food leaking holes are formed in the outer wall of the feeding barrel. A plurality of branch-shaped stand column suites are further arranged on the stand column shaft above the feeding barrel. According to the feeding device, the non-toppling confrontable base is designed to be of a semi-spherical structure and has the function similar to a tumbler, the whole feeding device can swing back and forth, and when an animal pokes the abundant feeding device to swing, the semi-spherical non-toppling base can also drive the stand column shaft to finally return to the vertical position; the flexibility and interestingness of animal ingestion can be improved, the activities of animals are effectively enriched, the occurrence of engraving behaviors is reduced, and the animal welfare is improved.

Jaw health systems and methods are described in which headphone devices are used to generate metrics related to the jaw health of a user. In one aspect, headphone devices worn on either side of the jaw may each determine the number of bites and chews of a user during an ingestion process and may then generate an imbalance metric. In one aspect, the headphone devices may be used to determine a food or substance toughness during the ingestion process.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

According to the invention, the expression of GREB1 is knocked down in PVN of CD mice, the body weight and the one-week food intake of the mice are obviously improved, multiple biological indexes in plasma are obviously increased, the liver volume is obviously increased compared with a control group, the liver weight / body weight ratio is also obviously increased, lipid droplet deposition in the liver is obviously increased, and the expression level of adipogenic differentiation related proteins is obviously increased; the above prompts that after the expression of the GREB1 is knocked down by the PVN of the CD mouse, the NAFLD animal model can be obtained. The invention also discloses that after GREB1 is over-expressed by PVN of a mouse, the weight rise, total cholesterol and low-density lipoprotein increased in serum, increased liver volume and increased lipid droplet deposition in the liver of the mouse due to NAFLD diet induction can be improved. The above all prompt that the GREB1 agonist can prevent or treat the NAFLD disease.

The present disclosure provides a biodegradable device that is administered to a patient in the form of a compact, ingestible package. The device is self-expandable within the stomach upon contact with liquid to assume an expanded bulk structure within the stomach. The device has a folded configuration that facilitates ingestion by the patient and is designed to unfold and self-expand within the stomach upon ingestion due to expansion of a plurality of expandable cells comprising one or more gel-forming materials. The present disclosure provides such a device, methods of manufacturing the same, and building blocks thereof.

The present invention addresses the problem of providing a novel functionality of a Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623), and a method for producing the same, and more particularly, to provide a novel functionality of a Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623). A composition to be ingested by healthy neonates or infants who are born for a full month contains, as an active ingredient, one or more species selected from the group consisting of a cell of Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623), a culture of the cell, and a treated product of the cell. The composition is used for promoting colonization of bifidobacterium bacteria in intestinal flora, promoting maturation of intestinal function, inhibiting milk spilling or regulating immune function.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

The present invention relates to a colon cleansing composition with improved ease of administration. The composition minimizes side effects caused by excessive ingredient content in conventional colonic laxatives while providing equivalent or superior intestinal cleansing efficacy, thereby remarkably improving patient compliance and ingestion convenience. In addition, as an uncoated tablet requiring no separate coating processes, a preparation that maintains the quality of tablets such as rapid disintegration and does not have a bitter taste can be provided. The present invention provides a pharmaceutical formulation comprising the colon cleansing composition with improved ease of administration and a method for colon cleansing using the formulation, thereby realizing a patient-centered colon cleansing process and ultimately greatly contributing to the improvement of colonoscopy quality.

The invention includes an orally ingestible delivery system for delivering a therapeutic agent to a preselected more distal location within a gastrointestinal (GI) tract of a mammal, where the system includes the therapeutic agent and a differentially disruptable capsule system, wherein the differentially disruptable capsule system is dimensionally adapted for oral ingestion and for passage from a more proximal location in the GI tract to the preselected more distal location and wherein the differentially disruptable capsule system comprises a continuous frangible matrix enclosing the therapeutic agent compartment and having a plurality of areas of material inhomogeneity disposed within the continuous frangible matrix. The invention additionally includes methods of manufacturing the orally ingestible delivery system and methods of employing the system to deliver an effective amount of a therapeutic agent to a patient in need thereof.

In mass spectrometry, a deuterium-resolved mass spectrum of a gas sample that determines the composition of volatile metabolites excreted by a human or animal subject after ingestion of deuterated water. The deuterium-resolved mass spectrum is used to determine the presence or amount of at least one deuterated metabolite. In addition, a corresponding mass spectrometry system is also disclosed.